ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knoop, C
Right arrow Articles by De Vuyst, P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knoop, C
Right arrow Articles by De Vuyst, P
Eur Respir J 1997; 10: 2898-2901
Copyright © ERS Journals Ltd 1997

Case Studies

Pleural effusion during bromocriptine exposure in two patients with pre-existing asbestos pleural plaques: a relationship?

C Knoop, M Mairesse, C Lenclud, PA Gevenois, and P De Vuyst

Two patients with pleural plaques developed pleural effusion and subsequent diffuse pleural fibrosis 50 and 39 yrs after their first exposure to asbestos. The diagnosis of benign asbestos pleural effusion was suggested, but the work-up finally suggested bromocriptine-induced pleural disease in both patients. These two cases illustrate that drug-induced pleural effusion is an important differential diagnosis of benign asbestos pleural effusion. It is, moreover, possible that pre-existing asbestos pleural lesions, or even asbestos exposure, increases the risk of developing bromocriptine-induced pleural disease.


This article has been cited by other articles:


Home page
 ChestHome page
S. Y. Morelock and S. A. Sahn
Drugs and the Pleura
Chest, July 1, 1999; 116(1): 212 - 221.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the European Respiratory Society.